Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of WSD0922-FU in EGFR C797S-Mutant NSCLC After Osimertinib
2024-519713-65-00Phase 2Authorised
- Sponsor
- Wayshine Biopharm
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of WSD-0922 in non-small cell lung cancer (NSCLC), sponsored by Wayshine Biopharm. Primary endpoints: Recommended Phase II Dose (RP2D) and Objective Response Rate (ORR). Planned start Jul 2025; status: authorised.
02
Drugs
WSD-0922
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-519713-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519713-65-00.